Walleye Capital’s 60 Degrees Pharmaceuticals SXTP Stock Holding History

Walleye Capital’s Portfolio SXTP Stock Details SXTP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-428	Closed	-$104K	–	5883
2023 Q4	$104K	Sell	428 -152	-26%	-$26.5K	﹤0.01%	4030
2023 Q3	$103K	Buy	+580	New	+$241K	﹤0.01%	3923

Other funds holding SXTP

CBT

Central Bank & Trust Lexington, Kentucky $705M AUM 34.21% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Walleye Capital's SXTP Position: Q1 2024 in Review

Walleye Capital sold out of 60 Degrees Pharmaceuticals (SXTP) in Q1 2024, closing a stake of 428 shares — an estimated $104K sold.

Walleye Capital first reported a position in SXTP in Q3 2023 and held it in 2 quarters. The position peaked at $104K in Q4 2023. 7 funds tracked by Wall St. Rank hold SXTP as of Q1 2024.

Walleye Capital reported no remaining 60 Degrees Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
Walleye Capital sold 428 60 Degrees Pharmaceuticals shares in Q1 2024, an estimated $104K.
Walleye Capital first reported a position in 60 Degrees Pharmaceuticals in Q3 2023 and held it in 2 quarters.
Walleye Capital's 60 Degrees Pharmaceuticals position peaked at $104K in Q4 2023.
7 funds tracked by Wall St. Rank held 60 Degrees Pharmaceuticals as of Q1 2024.

Based on Walleye Capital's 13F filing for Q1 2024, filed 15 May 2024.